Link to this page
Biological and Environmental Research Ontology
Preferred Name | Cytarabine | |
Synonyms |
|
|
Definitions |
An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04) |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C408 |
|
Accepted_Therapeutic_Use_For |
Acute lymphocytic leukemia; Acute Nonlymphocytic leukemia; Bone marrow transplantation; Carcinomatous meningitis; Chronic myelogenous leukemia; Hogkins disease; Meningeal leukemia; Acute Myeloid Leukemia; Meningitis lymphomatous; Myelodysplasic syndrome; Non-Hodgkins lymphoma; Ovarian cancer, intraperitoneal treatment; Retinoblastoma
|
|
ALT_DEFINITION |
A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.
|
|
CAS_Registry |
147-94-4
|
|
CHEBI_ID |
CHEBI:28680
|
|
Chemical_Formula |
C9H13N3O5
|
|
code |
C408
|
|
Contributing_Source |
CTRP FDA PCDC
|
|
definition |
An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)
|
|
Display_Name |
Cytarabine
|
|
FDA_UNII_Code |
04079A1RDZ
|
|
Has_Salt_Form | ||
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C186341 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C174019 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C186327 http://purl.obolibrary.org/obo/NCIT_C186328 http://purl.obolibrary.org/obo/NCIT_C157711 |
|
Is_PCDC_AML_Permissible_Value_For_Variable | ||
Is_Value_For_GDC_Property | ||
label |
Cytarabine
|
|
Legacy Concept Name |
Cytosine_Arabinoside
|
|
Maps_To |
Cytarabine
|
|
NCI_Drug_Dictionary_ID |
39015
|
|
NSC Number |
287459
|
|
PDQ_Closed_Trial_Search_ID |
39015
|
|
PDQ_Open_Trial_Search_ID |
39015
|
|
Preferred_Name |
Cytarabine
|
|
prefixIRI |
NCIT:C408
|
|
prefLabel |
Cytarabine
|
|
Semantic_Type |
Pharmacologic Substance Nucleic Acid, Nucleoside, or Nucleotide
|
|
UMLS_CUI |
C0010711
|
|
subClassOf |
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |